Based on the key indicators related to NLS Pharmaceutics' liquidity, profitability, solvency, and operating efficiency, NLS Pharmaceutics AG may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, NLS Pharmaceutics' Other Current Assets are relatively stable compared to the past year. As of 03/23/2025, Total Current Assets is likely to grow to about 3.1 M, while Total Stockholder Equity is likely to drop (10.7 M). Key indicators impacting NLS Pharmaceutics' financial strength include:
The essential information of the day-to-day investment outlook for NLS Pharmaceutics includes many different criteria found on its balance sheet. An individual investor should monitor NLS Pharmaceutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in NLS Pharmaceutics.
NLS Pharmaceutics competes with Indaptus Therapeutics, Pasithea Therapeutics, Quoin Pharmaceuticals, Lixte Biotechnology, and Anebulo Pharmaceuticals. NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company was incorporated in 2015 and is based in Zurich, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what NLS Pharmaceutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining NLS Pharmaceutics's current stock value. Our valuation model uses many indicators to compare NLS Pharmaceutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NLS Pharmaceutics competition to find correlations between indicators driving NLS Pharmaceutics's intrinsic value. More Info.
NLS Pharmaceutics AG is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, NLS Pharmaceutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NLS Pharmaceutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
NLS Pharmaceutics Systematic Risk
NLS Pharmaceutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NLS Pharmaceutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on NLS Pharmaceutics correlated with the market. If Beta is less than 0 NLS Pharmaceutics generally moves in the opposite direction as compared to the market. If NLS Pharmaceutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NLS Pharmaceutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NLS Pharmaceutics is generally in the same direction as the market. If Beta > 1 NLS Pharmaceutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in NLS Pharmaceutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NLS Pharmaceutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NLS Pharmaceutics growth as a starting point in their analysis.
NLS Pharmaceutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NLS Pharmaceutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NLS Pharmaceutics AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of NLS Pharmaceutics AG based on widely used predictive technical indicators. In general, we focus on analyzing NLS Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NLS Pharmaceutics's daily price indicators and compare them against related drivers.
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.